Cardiotoxicity can be reduced in women with HER2-positive breast cancer being treated with doxyrubicin and trastuzumab (Herceptin) through the use of ACE inhibitors or beta blockers. The findings, presented at the American College of Cardiology’s 67th Annual Scientific Session in Orlando, showed lower cardiac event rates with ACE inhibitors (37%) and beta-blockers (31%) compared to ...
Two agents prevent cardiotoxicity in treatment for HER2-positive breast cancer
By Mardi Chapman
13 Mar 2018